Progress review of the European Paediatric Regulatory Framework after six years of implementation

Area of Science:

• Pharmacology
• Regulatory Science
• Pediatric Medicine

Background:

• The European Union (EU) 1901/2006 Paediatric Regulation, effective since 2007, mandated changes in pediatric drug development.
• The pharmaceutical industry has adapted significantly to this regulation over the past five years.
• This has led to a substantial increase in the development of new candidate drugs for pediatric use.

Purpose of the Study:

• To review the changes implemented in pediatric drug development due to the EU Paediatric Regulation.
• To identify aspects of pediatric drug development that still require attention.
• To guide future efforts in providing better medicines for children.

Main Methods:

• Review of implemented changes in the pharmaceutical industry.
• Analysis of the impact of the Paediatric Regulation.
• Identification of ongoing challenges and future research directions.

Main Results:

• The Paediatric Regulation has driven significant changes in drug development strategies for children.
• The pharmaceutical industry has incorporated numerous modifications in response to the regulation.
• Several areas within pediatric drug development still require further advancements.

Conclusions:

• The EU Paediatric Regulation has been a catalyst for progress in pediatric medicine.
• Continued focus on specific developmental aspects is crucial for optimizing children's pharmaceutical treatments.
• Future work should address identified gaps to ensure the availability of safe and effective medicines for pediatric populations.